AP
Apogee Therapeutics, Inc.
APGE · NASDAQ
$135.07 +0.01% (+$0.01)
1M +0.36%
Market Cap $8.36B
P/E Ratio -
Div. Yield -
ROE 29.88%
Piotroski F-Score Weak
2/9Valuation
13 /100
Expensive P/B 7.00x
P/E N/A
EV/EBITDA N/A
Growth
100 /100
Growing Book val. growth 85.30%
EPS growth N/A
Rev. growth N/A
Profitability
-
N/A Gross margin N/A
Net margin N/A
Op. margin N/A
Quality
0 /100
Poor ROIC 25.25%
ROE 29.88%
ROA 22.04%
Debt
69 /100
Low Debt/Equity 0.01x
Current ratio 26.44x
Int. coverage -185.14x
Stability
33 /100
Unstable Beta 0.34x
EPS volatility 44.58%
Profitable years 0
Bulios Scoring descrie calitatea și istoricul unei companii, nu randamentul viitor. Un scor ridicat nu este un semnal de cumpărare. Află mai multe
Întreabă StockBot despre APGE
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Michael Thomas Henderson
Employees
261
Headquarters
Waltham
Evenimente viitoare
09 NOV.
Earnings
Upcoming earnings report